Charles River Laboratories International, Inc. (CRL) — ESG & Values Scores

Environment story

Charles River's environmental profile is materially constrained by undisclosed Scope 1 & 2 emissions, absent net-zero target, and significant Scope 3 exposure from animal research operations and supply-chain dependencies. The company has not published GHG inventory data or science-based targets in accessible corporate sustainability filings. Notable resource-use controversies include NHP (non-human primate) supply-chain legal disputes (DOJ/USFWS investigations 2023; resumed Cambodia imports November 2025 post-CITES clearance), habitat/conservation area concerns, and contamination risks requiring facility remediation. No verified direct decarbonization infrastructure investments disclosed. Environmental score reflects starting penalty for undisclosed emissions (-15), absent/post-2045 net-zero target (-15), and supply-chain/habitat controversies (-10). Animal research model dependency creates structural ESG tension with emerging regulatory shifts toward alternative methodologies (FDA April 2025 NAM expansion, UK November 2025 animal-test phase-out roadmap).

Criticisms on file

DOJ and USFWS investigation (2023) into Cambodia non-human primate imports; company voluntarily suspended shipments until procedures agreed; resumed November 2025.
Source: CRL 10-K Item 1A Risk Factors; CRL 10-K Item 3 Legal Proceedings
Habitat and conservation-area concerns from environmental activists regarding animal research facility locations in or near protected/conservation areas; potential legal challenges and advocacy for environmental restrictions.
Source: CRL 10-K Item 1A Risk Factors - 'Negative attention from special interest groups may impair our business'
Contamination events in animal populations causing inventory loss, facility disinfection, and potential impact on client facilities; complex mechanical systems subject to periodic failure.
Source: CRL 10-K Item 1A Risk Factors - 'Contaminations in our animal populations can damage our inventory'
Limited source of supply for non-human primates subject to export/import restrictions, tariffs, disease outbreaks, and geopolitical disruptions; supply constraints create dynamic pricing and inventory risk.
Source: CRL 10-K Item 1A Risk Factors - 'Several of our product and service offerings...are dependent on a limited source of supply'

Disclosed initiatives

3Rs Initiative (Replacement, Reduction, Refinement)

Commitment to explore new technologies to refine and potentially reduce use of animal models and animal-derived products as in vitro and in silico methods become validated.

Aspirational but not quantified; no published roadmap or timelines disclosed.
NHP Supply-Chain Remediation

Post-2023 DOJ investigation, resumed Cambodia NHP imports November 2025 following USFWS CITES clearance and implementation of purpose-bred verification procedures.

Mitigates reputational/legal risk but does not reduce operational emissions or environmental footprint.

Social story

Charles River demonstrates moderate social performance with documented diversity initiatives, pay equity audits, and community engagement, but faces material constraints from an elevated CEO-to-median-worker pay ratio (251:1, well above 200:1 threshold) and undisclosed union-standing data. Leadership diversity metrics are not explicitly quantified in proxy filings; board composition shows gender representation (3 of 12 directors identified as female), but executive-team diversity ratios remain opaque. The company reports global pay-equity audits and biennial pay assessments, employee resource groups (4,000+ members), and STEM/community programs. No active union-suppression allegations or major strikes documented in 24-month window. Supply-chain labor scrutiny focuses on NHP procurement (Cambodia legal matters) rather than traditional manufacturing-sector human-rights violations (e.g., conflict minerals). Score reflects deduction for CEO pay ratio (-15), partial deduction for leadership diversity disclosure gaps (-10), and modest credit for stated pay-equity audits and community programs (+5).

Criticisms on file

CEO-to-median-worker pay ratio of 251:1 (CEO total compensation $15.4M vs. median employee $61,430), significantly exceeding industry peers and governance best practice thresholds.
Source: CRL Proxy DEF 14A 2026 - '2025 Pay Ratio Disclosure'
Non-human primate supply-chain labor concerns related to Cambodia supplier DOJ prosecution and export restrictions; no independent supply-chain labor audits disclosed.
Source: CRL 10-K Item 1A Risk Factors - 'Several of our product and service offerings...are dependent on a limited source of supply'

Disclosed initiatives

Global Pay Equity Program

Biennial global pay assessments conducted; pay equity audits in countries where legally required; corrective action taken where appropriate.

Proactive but not independently verified; no published pay-gap benchmarks or audit results disclosed.
Employee Resource Groups (ERGs)

Company maintains ERGs open to all employees; over 4,000 members reported to support inclusion and belonging.

Demonstrates commitment to internal diversity and engagement infrastructure.
Community & STEM Investment

Three priority community areas: Thriving Communities (basic human services access), STEM Education (next-generation scientists), Health Outcomes (disease education/awareness); both time and philanthropic giving commitment stated.

Positive social impact but magnitude of investment and outcomes metrics not quantified in filings.
Diversity & Inclusion Leadership

Stated commitment to 'best in class' DEI by engaging people, enhancing career development, prioritizing employee well-being, and analyzing data/feedback.

Governance commitment documented but specific D&I targets, benchmarks, and third-party verification not disclosed.

Governance story

Charles River exhibits moderately strong governance infrastructure with independent board structure, separation of Chair and CEO (effective May 2026 leadership transition), majority-independent audit/compensation committees, and formal compliance frameworks. Board independence is estimated at ~83% (10 of 12 directors independent, excluding CEO Foster and director Ceesay). No dual-class voting structure exists. However, governance score is constrained by: (1) limited lobbying-spend transparency regarding environmental/regulatory advocacy positions; (2) CDMO manufacturing compliance concerns (January 2025 FDA 483 form at facility; client clinical holds; October 2025 successful pre-license inspection—material regulatory risk); (3) data-privacy/cybersecurity regulatory exposure (GDPR, CCPA, PIPL, UK GDPR) with articulated compliance costs but no quantified breach history since 2019; (4) no disclosed shareholder activism or blocked climate/ESG proposals. The company demonstrates commitment to code of conduct, stock ownership requirements, clawback policies, and annual board assessments. Lead Independent Director role and imminent transition to fully independent Chair provide governance strengthening.

Criticisms on file

CDMO facility regulatory compliance: January 2025 FDA complete response letter on one biologics license application and clinical holds placed on client IND applications following pre-license inspection observations; FDA Form 483 Notice of Inspectional Observations issued; October 2025 successful pre-license inspection conducted.
Source: CRL 10-K Item 1A Risk Factors - 'CDMO services are highly complex and failure to provide quality and timely services...'
Data privacy and cybersecurity regulatory exposure under GDPR, CCPA, PIPL, UK GDPR, and U.S. state data-breach notification laws; potential fines, civil penalties, and litigation risk; AI-based systems introduce additional cybersecurity and data-protection risks.
Source: CRL 10-K Item 1A Risk Factors - 'Failure to comply with U.S., state, local or international environmental, health, safety and sustainability laws...'; 'We are required to comply with stringent, complex and evolving laws...relating to data privacy and security'
Cybersecurity threat history: material information security breach/incident in 2019 (not further detailed); ongoing business email compromise fraud targeting illegitimate bank accounts (no material losses reported); third-party software/SaaS providers subject to cyber incidents.
Source: CRL 10-K Item 1A Risk Factors - 'We have in the past experienced and in the future could experience unauthorized access into our information systems'
Strategic review and potential divestiture process (announced May 2025, updated November 2025) creates uncertainty, potential for management distraction, and stock-price volatility; outcome contingent on market conditions, regulatory approvals, and financing availability.
Source: CRL 10-K Item 1A Risk Factors - 'Our review of potential strategic alternatives may not result in an executed or consummated transaction...'

Disclosed initiatives

Board Leadership Transition & Governance Enhancement

James Foster retiring as CEO and Chair (May 2026); Birgit Girshick succeeds as CEO; Martin Mackay becomes independent Chair. Separation of CEO/Chair roles effective at annual meeting.

Eliminates founder-CEO concentration risk; enhances board independence and oversight.
Lead Independent Director Role

Dr. Martin Mackay serves as Lead Independent Director with broad authority over board agendas, executive sessions, shareholder liaison, and annual review of lead director responsibilities.

Strong independent governance infrastructure; prepares transition to Chair role.
Formal Corporate Governance Guidelines & Code of Conduct

Mandatory code of ethics for all employees and officers; governance guidelines specify director independence standards, committee composition, and oversight processes; annual board assessments.

Framework-level compliance infrastructure; aligned with NYSE/SEC standards.
Stock Ownership & Clawback Policies

Stock ownership requirements for VP-level and above (1x-6x salary depending on role); clawback policy on executive compensation in event of material accounting restatement.

Aligns executive incentives with shareholder value and long-term performance.
Political Contribution Policy

Policy prohibits use of company resources to fund political parties/candidates/officials without approval from CEO, CFO, General Counsel; restricts employee personal political activity funding.

Transparency and control framework; no disclosed PAC contributions or lobbying spend in proxy.
Data Privacy & Cybersecurity Governance

Audit Committee oversees information security risk; compliance with GDPR, CCPA, PIPL, UK GDPR articulated; contemporary validation practices for IT infrastructure; ongoing enhancement of security safeguards.

Proactive but does not eliminate regulatory exposure; no material breach since 2019 disclosed.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Charles River Laboratories International, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Charles River Laboratories International, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)